Menu Back toSession 8: The Future of RWE – Emerging Trends and Opportunities to Benefit Patients and Closing Remarks

Real-World Evidence Conference

Translating Insights into Real-World Value.


Session 8: The Future of RWE – Emerging Trends and Opportunities to Benefit Patients and Closing Remarks

Session Chair(s)

Dorothee B Bartels, PhD, MSc

Dorothee B Bartels, PhD, MSc

  • Head of Global Real World Evidence and Digital Science
  • UCB, Germany
Paul M. Coplan, DrSc, MBA, MSc, FISPE

Paul M. Coplan, DrSc, MBA, MSc, FISPE

  • VP, Medical Device Epidemiology & Real-World Data Analytics
  • Johnson & Johnson, United States
This session will explore emerging trends for the future of Real World Evidence (RWE) and the complementary value of advanced analytics. The speakers will focus on the growing role of RWE for decision making, using the approach of emulating Randomized Controlled Trials (RCTs). We will address how new sources of data can be combined with more traditional research databases to provide much richer and more informative data for conducting studies, such as Patient Generated Health Data (PGHD), omics, and imaging. The session will also address challenges in combining advanced analytics with more established designs and methods. Advances in using AI-based image analysis of tumors that will facilitate the inclusion of AI-analyzed tumor images into classical RWE databases with be reviewed. Finally, the topic of how the UK researchers have been able to include genomic data into EHR databases for the purposes of RWE studies will be discussed.
Learning Objective : At the conclusion of this session, participants should be able to:
  • Identify the complementary value of RWE to clinical trials
  • Envision new RWD sources for RWE generation and understand their challenges and opportunities
  • Evaluate some of the opportunities and risks when including ML/AI in their RWE research

Speaker(s)

William  Marks, MD, MS

Speaker

William Marks, MD, MS

  • Head of Clinical Science & Head of Neurology
  • Verily Life Sciences, United States
Sebastian  Schneeweiss, DrSc, MD

Speaker

Sebastian Schneeweiss, DrSc, MD

  • Professor, Medicine and Epidemiology; Chief of the Div of Pharmacoepidemiology
  • Harvard Medical School and Brigham and Women's Hospital, United States
Pallavi  Tiwari, PhD

Speaker

Pallavi Tiwari, PhD

  • Assistant Professor of Biomedical Engineering, School of Medicine
  • Case Western Reserve University , United States